Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis

Open access
Mathewson, Nathan D., Ashenberg, Orr, Tirosh, Itay, Gritsch, Simon, Perez, Elizabeth M., Marx, Sascha, Jerby-Arnon, Livnat, Chanoch-Myers, Rony, Hara, Toshiro, Richman, Alyssa R., Ito, Yoshinaga, Pyrdol, Jason, Friedrich, Mirco, Schumann, Kathrin, Poitras, Michael J., Gokhale, Prafulla C., Gonzalez Castro, L. Nicolas, Shore, Marni E., Hebert, Christine M., Shaw, Brian, Cahill, Heather L., Drummond, Matthew, Zhang, Wubing, Olawoyin, Olamide, Wakimoto, Hiroaki, Rozenblatt-Rosen, Orit, Brastianos, Priscilla K., Liu, X. Shirley, Jones, Pamela S., Cahill, Daniel P., Frosch, Matthew P., Louis, David N., Freeman, Gordon J., Ligon, Keith L., Marson, Alexander, Chiocca, E. Antonio, Reardon, David A., Regev, Aviv, Suvà, Mario L., Wucherpfennig, Kai W.·2021·Cell

Abstract

SUMMARY T cells are critical effectors of cancer immunotherapies, but little is known about their gene expression programs in diffuse gliomas. Here, we leverage single-cell RNA-seq to chart the gene expression and clonal landscape of tumor-infiltrating T cells across 31 patients with IDH-wildtype glioblastoma and IDH-mutant glioma. We identify potential effectors of anti-tumor immunity in subsets of T cells that co-express cytotoxic programs and several NK cell genes. Analysis of clonally expanded tumor-infiltrating T cells further identifies the NK gene KLRB1 (encoding CD161) as a candidate inhibitory receptor. Accordingly, genetic inactivation of KLRB1 or antibody-mediated CD161 blockade enhances T cell-mediated killing of glioma cells in vitro and their anti-tumor function in vivo. KLRB1 and its associated transcriptional program are also expressed by substantial T cell populations in other human cancers. Our work provides an atlas of T cells in gliomas and highlights CD161 and other NK cell receptors as immunotherapy targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2021.01.022

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 408

Metadata

Authors
Mathewson, N. D., Ashenberg, O., Tirosh, I., Gritsch, S., Perez, E. M., Marx, S., Jerby-Arnon, L., Chanoch-Myers, R., Hara, T., Richman, A. R., Ito, Y., Pyrdol, J., Friedrich, M., Schumann, K., Poitras, M. J., Gokhale, P. C., Gonzalez Castro, L. N., Shore, M. E., Hebert, C. M., Shaw, B., Cahill, H. L., Drummond, M., Zhang, W., Olawoyin, O., Wakimoto, H., Rozenblatt-Rosen, O., Brastianos, P. K., Liu, X. S., Jones, P. S., Cahill, D. P., Frosch, M. P., Louis, D. N., Freeman, G. J., Ligon, K. L., Marson, A., Chiocca, E. A., Reardon, D. A., Regev, A., Suvà, M. L., & Wucherpfennig, K. W.
Venue
Cell
Publisher
Elsevier BV
Published
2021-03
Volume
184
Issue
5
Pages
1281-1298.e26
ISSN
0092-8674 (ISSN-L)
OpenAlex
W3131460561
Cited by
408
References
66
FWCI
22.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. https://app.cochat.ai/papers/10.1016/j.cell.2021.01.022
The paper
Mathewson, N. D., Ashenberg, O., Tirosh, I., Gritsch, S., Perez, E. M., Marx, S., Jerby-Arnon, L., Chanoch-Myers, R., Hara, T., Richman, A. R., Ito, Y., Pyrdol, J., Friedrich, M., Schumann, K., Poitras, M. J., Gokhale, P. C., Gonzalez Castro, L. N., Shore, M. E., Hebert, C. M., . . . Wucherpfennig, K. W. (2021). Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. https://doi.org/10.1016/j.cell.2021.01.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.